NCT01016665

Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy

Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Federal University of São Paulo · Academic / Other
• Sex: Female
• Age: 40 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Background: Identification of new biomarkers with potential predictive and prognostic role has contributed unequivocally to breast cancer treatment. Although traditionally endocrine therapy is based on hormonal receptors status (estrogen - ER and progesterone- PR), some patients become hormone resistant. In order to identify a possible profile associated to hormonal resistance, some biomarkers have been assessed after short period primary hormone therapy (HT). Objectives: To compare the expression of Ki-67, Bcl2, Bax, Bak, ER and e PR in postmenopausal women with ER positive invasive ductal carcinomas (IDC), prior and after tamoxifen and anastrozole in short term hormone therapy.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Anastrozole	Tamoxifen 20mg and anastrozole 1 mg

Timeline

• Start date: 2005-04-01
• Primary completion: 2007-07-01
• Completion: 2008-06-01
• First posted: 2009-11-19
• Last updated: 2009-11-19

Locations

1 site across 1 country: Brazil